Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASE Technology Holding Co Ltd (ASX) vs Cassava Sciences Inc (FLNA) Price & Performance

ASE Technology Holding Co Ltd
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

ASE Technology Holding Co Ltd vs Cassava Sciences Inc — how do they compare? ASE Technology Holding Co Ltd trades at $41.78 (market cap $92.88B), while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: ASE Technology Holding Co Ltd is far larger — about 1615.6× Cassava Sciences Inc's market cap, and ASE Technology Holding Co Ltd pays a 0.98% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

ASXFLNA
Market Cap
$92.88B$57.49M
Sector
TechnologyHealth
52-Week High
$45.12$4.64
52-Week Low
$9.50$1.16
Enterprise Value
$97.32B-$29.09M
Dividend Yield
0.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASE Technology Holding Co Ltd

ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.

Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASE Technology Holding Co Ltd

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Read more on ASX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA